AUS
NZ
UK
CA
USA
IND
Vitasora Health Limited (ASX: VHL; OTCQB: VHLUF), a Melbourne-based digital connected care company operating within the US healthcare sector, has issued 800,000 fully paid ordinary shares as payment to brokers involved in its placement capital raising initially announced on 11 June 2026. This share issuance occurred on 2 July 2026 and was accompanied by a Section 708A cleansing notice filed on 3 July 2026, confirming the shares were issued without formal disclosure under Part 6D.2 of the Corporations Act 2001. The cleansing notice is a routine regulatory requirement that permits the newly issued shares to be traded freely on the ASX without restrictions. Investors monitoring Vitasora's capital structure and compliance post-placement should note the company also lodged a corresponding Appendix 2A with the exchange simultaneously.<\/p> <\/div>
Key Points<\/h3>
- Company: Vitasora Health Limited (ASX: VHL; OTCQB: VHLUF)<\/li>
- Issued 800,000 fully paid ordinary shares on 2 July 2026 as broker fee under the placement announced on 11 June 2026<\/li>
- Section 708A cleansing notice filed on 3 July 2026 enabling unrestricted trading of the new shares<\/li>
- Company confirms adherence to Chapter 2M of the Corporations Act and continuous disclosure requirements under sections 674 and 674A as of the notice date<\/li>
- No excluded information exists as of the notice date that would impact investor assessment of the company’s financial or security status<\/li>
- Appendix 2A relating to the share issue was released concurrently<\/li>
- Investors should monitor updates on the use of proceeds from the June 2026 placement and operational progress in Vitasora’s US remote patient monitoring business<\/li>
<\/ul>
<\/div>
Details of the June 2026 Placement Leading to Broker Fee Share Issuance<\/h2>
The 800,000 shares issued on 2 July 2026 stem directly from Vitasora Health’s placement capital raising announced on 11 June 2026. This placement raised new equity capital, with the broker fee shares representing compensation to the broker facilitating the transaction—a common practice in Australian capital markets where brokers receive equity in lieu of cash.<\/p>
The company update did not restate the total value of the broker fee shares or the full size of the placement. Investors seeking these figures should consult the original 11 June 2026 placement announcement. The current notice confirms the broker fee shares have now been formally issued and settled, completing a critical post-placement administrative step.<\/p>
Implications of the Section 708A Cleansing Notice for Shareholders<\/h2>
The Section 708A cleansing notice under the Corporations Act 2001 (Cth) permits shares issued without a formal prospectus or product disclosure statement to be traded freely on the ASX. Absent this notice, shares issued to sophisticated or professional investors typically carry a 12-month resale restriction. By lodging the cleansing notice, Vitasora has removed this restriction for the 800,000 broker fee shares, allowing holders to sell these shares on market without regulatory barriers.<\/p>
For current shareholders, the cleansing notice does not alter the company’s operational outlook or financial position. However, it is a legally significant declaration requiring the board to confirm full compliance with continuous disclosure obligations and that no material information has been withheld. Vitasora’s board has made these confirmations in the notice, providing regulatory assurance to shareholders.<\/p>
Vitasora’s Declaration of Continuous Disclosure Compliance Under Sections 674 and 674A<\/h2>
In accordance with Section 708A(5)(e) of the Corporations Act, Vitasora’s notice affirms compliance with Chapter 2M of the Act, governing financial reporting, and sections 674 and 674A related to continuous disclosure under ASX Listing Rules. This statutory declaration confirms that, to the board’s knowledge, all material information has been disclosed promptly.<\/p>
The company also states there is no "excluded information" as defined in sections 708A(7) and 708A(8), meaning no undisclosed information exists that would affect a reasonable investor’s decision. This serves as an important compliance milestone, affirming the integrity of Vitasora’s disclosure practices at this time.<\/p>
Function of Appendix 2A in Registering the New Shares on the ASX<\/h2>
Alongside the cleansing notice, Vitasora filed an Appendix 2A with the ASX on 3 July 2026. This document formally applies for the 800,000 newly issued shares to be quoted and listed for trading on the ASX. It supplies the exchange with details necessary to update the company’s share register and list the shares as tradeable securities.<\/p>
The concurrent filing of both documents demonstrates a coordinated, compliant approach to post-placement administration, ensuring no delay between legal clearance for trading and the operational listing of the shares. This protects both the broker’s interests and market integrity.<\/p>
Impact of Broker Fee Shares on Vitasora’s Share Capital<\/h2>
The 800,000 fully paid ordinary shares issued as broker fees increase Vitasora’s total shares on issue. Although the company did not restate its pre-notice share count, this addition will be reflected once the Appendix 2A is processed and the share registry updated.<\/p>
Investors concerned with dilution should consider the broker fee shares as part of the overall capital raising completed in June 2026. The total dilutive effect, including primary placement shares and broker fees, can be assessed by reviewing the original 11 June 2026 placement announcement alongside the Appendix 2A filed with this notice. Updated total shares on issue were not disclosed in this announcement.<\/p>
Strategic Context: Vitasora’s US Remote Patient Monitoring Business and Capital Raising<\/h2>
Vitasora Health operates in the US healthcare market, providing remote patient monitoring (RPM) and chronic care management (CCM) services to healthcare providers. Its connected care platform integrates clinical teams with technology to offer a turnkey solution for value-based care providers. Headquartered in Melbourne, the company also maintains offices in Los Angeles.<\/p>
Capital raises like the June 2026 placement are closely watched as indicators of the company’s funding runway and ability to scale US operations. Although this update does not specify the use of proceeds, the funds are likely intended to support ongoing commercial expansion. Investors may look for future updates on new provider partnerships, patient enrolment milestones, or revenue guidance to understand capital deployment.<\/p>
Vitasora’s wheezo4 Device: A Differentiator in Remote Patient Monitoring<\/h2>
A key asset is the wheezo4 medical device, described as a world-first FDA-approved Class II device and the only wheeze-rate detector integrated into RPM programs. It analyzes breath sounds to detect wheeze and works with the respiri12 app, enabling patients to log symptoms and triggers, building a clinical profile that supports physician-patient communication.<\/p>
This device differentiates Vitasora from generic telehealth or RPM providers by offering a proprietary hardware-software ecosystem focused on respiratory disorders, a major chronic condition in the US. FDA Class II approval provides market access and competitive protection. As Vitasora expands US provider partnerships, wheezo4 remains central to its commercial strategy and investor appeal.<\/p>
Leadership Overseeing Vitasora’s Capital Market Activities<\/h2>
The update was authorised by Vitasora’s Board of Directors. The primary contacts for investor and media enquiries are Mr Marjan Mikel, Chief Executive Officer and Managing Director, and Mr Nicholas Smedley, Non-Executive Chairman. Mr Mikel serves as the main operational contact, while Mr Smedley provides governance oversight.<\/p>
The involvement of both CEO and Non-Executive Chairman as contacts highlights the board-level accountability for the statutory declarations in the Section 708A cleansing notice. These confirmations carry legal significance under Australian corporate law and demonstrate the board’s commitment to compliance.<\/p>
Market Impact and Investor Considerations Following the Share Issuance<\/h2>
The immediate effect on Vitasora’s share price from the cleansing notice and broker fee issuance was not publicly clear. Typically, such post-placement administrative steps are neutral since the market has already priced in dilution from the original placement announcement on 11 June 2026. However, now that the broker fee shares are freely tradeable, additional supply could enter the market if the broker chooses to sell.<\/p>
Looking forward, investors should monitor announcements regarding the deployment of funds raised in June 2026, updates on the US provider network and patient enrolment, as well as quarterly cash flow reports providing insight into revenue and operating costs. Vitasora’s dual listing on the OTCQB in the US under ticker VHLUF also attracts international investor interest, particularly in digital health and remote patient monitoring sectors.<\/p>
Details of the June 2026 Placement Leading to Broker Fee Share Issuance<\/h2>
The 800,000 shares issued on 2 July 2026 stem directly from Vitasora Health’s placement capital raising announced on 11 June 2026. This placement raised new equity capital, with the broker fee shares representing compensation to the broker facilitating the transaction—a common practice in Australian capital markets where brokers receive equity in lieu of cash.<\/p>
The company update did not restate the total value of the broker fee shares or the full size of the placement. Investors seeking these figures should consult the original 11 June 2026 placement announcement. The current notice confirms the broker fee shares have now been formally issued and settled, completing a critical post-placement administrative step.<\/p>
Implications of the Section 708A Cleansing Notice for Shareholders<\/h2>
The Section 708A cleansing notice under the Corporations Act 2001 (Cth) permits shares issued without a formal prospectus or product disclosure statement to be traded freely on the ASX. Absent this notice, shares issued to sophisticated or professional investors typically carry a 12-month resale restriction. By lodging the cleansing notice, Vitasora has removed this restriction for the 800,000 broker fee shares, allowing holders to sell these shares on market without regulatory barriers.<\/p>
For current shareholders, the cleansing notice does not alter the company’s operational outlook or financial position. However, it is a legally significant declaration requiring the board to confirm full compliance with continuous disclosure obligations and that no material information has been withheld. Vitasora’s board has made these confirmations in the notice, providing regulatory assurance to shareholders.<\/p>
Vitasora’s Declaration of Continuous Disclosure Compliance Under Sections 674 and 674A<\/h2>
In accordance with Section 708A(5)(e) of the Corporations Act, Vitasora’s notice affirms compliance with Chapter 2M of the Act, governing financial reporting, and sections 674 and 674A related to continuous disclosure under ASX Listing Rules. This statutory declaration confirms that, to the board’s knowledge, all material information has been disclosed promptly.<\/p>
The company also states there is no "excluded information" as defined in sections 708A(7) and 708A(8), meaning no undisclosed information exists that would affect a reasonable investor’s decision. This serves as an important compliance milestone, affirming the integrity of Vitasora’s disclosure practices at this time.<\/p>
Function of Appendix 2A in Registering the New Shares on the ASX<\/h2>
Alongside the cleansing notice, Vitasora filed an Appendix 2A with the ASX on 3 July 2026. This document formally applies for the 800,000 newly issued shares to be quoted and listed for trading on the ASX. It supplies the exchange with details necessary to update the company’s share register and list the shares as tradeable securities.<\/p>
The concurrent filing of both documents demonstrates a coordinated, compliant approach to post-placement administration, ensuring no delay between legal clearance for trading and the operational listing of the shares. This protects both the broker’s interests and market integrity.<\/p>
Impact of Broker Fee Shares on Vitasora’s Share Capital<\/h2>
The 800,000 fully paid ordinary shares issued as broker fees increase Vitasora’s total shares on issue. Although the company did not restate its pre-notice share count, this addition will be reflected once the Appendix 2A is processed and the share registry updated.<\/p>
Investors concerned with dilution should consider the broker fee shares as part of the overall capital raising completed in June 2026. The total dilutive effect, including primary placement shares and broker fees, can be assessed by reviewing the original 11 June 2026 placement announcement alongside the Appendix 2A filed with this notice. Updated total shares on issue were not disclosed in this announcement.<\/p>
Strategic Context: Vitasora’s US Remote Patient Monitoring Business and Capital Raising<\/h2>
Vitasora Health operates in the US healthcare market, providing remote patient monitoring (RPM) and chronic care management (CCM) services to healthcare providers. Its connected care platform integrates clinical teams with technology to offer a turnkey solution for value-based care providers. Headquartered in Melbourne, the company also maintains offices in Los Angeles.<\/p>
Capital raises like the June 2026 placement are closely watched as indicators of the company’s funding runway and ability to scale US operations. Although this update does not specify the use of proceeds, the funds are likely intended to support ongoing commercial expansion. Investors may look for future updates on new provider partnerships, patient enrolment milestones, or revenue guidance to understand capital deployment.<\/p>
Vitasora’s wheezo4 Device: A Differentiator in Remote Patient Monitoring<\/h2>
A key asset is the wheezo4 medical device, described as a world-first FDA-approved Class II device and the only wheeze-rate detector integrated into RPM programs. It analyzes breath sounds to detect wheeze and works with the respiri12 app, enabling patients to log symptoms and triggers, building a clinical profile that supports physician-patient communication.<\/p>
This device differentiates Vitasora from generic telehealth or RPM providers by offering a proprietary hardware-software ecosystem focused on respiratory disorders, a major chronic condition in the US. FDA Class II approval provides market access and competitive protection. As Vitasora expands US provider partnerships, wheezo4 remains central to its commercial strategy and investor appeal.<\/p>
Leadership Overseeing Vitasora’s Capital Market Activities<\/h2>
The update was authorised by Vitasora’s Board of Directors. The primary contacts for investor and media enquiries are Mr Marjan Mikel, Chief Executive Officer and Managing Director, and Mr Nicholas Smedley, Non-Executive Chairman. Mr Mikel serves as the main operational contact, while Mr Smedley provides governance oversight.<\/p>
The involvement of both CEO and Non-Executive Chairman as contacts highlights the board-level accountability for the statutory declarations in the Section 708A cleansing notice. These confirmations carry legal significance under Australian corporate law and demonstrate the board’s commitment to compliance.<\/p>
Market Impact and Investor Considerations Following the Share Issuance<\/h2>
The immediate effect on Vitasora’s share price from the cleansing notice and broker fee issuance was not publicly clear. Typically, such post-placement administrative steps are neutral since the market has already priced in dilution from the original placement announcement on 11 June 2026. However, now that the broker fee shares are freely tradeable, additional supply could enter the market if the broker chooses to sell.<\/p>
Looking forward, investors should monitor announcements regarding the deployment of funds raised in June 2026, updates on the US provider network and patient enrolment, as well as quarterly cash flow reports providing insight into revenue and operating costs. Vitasora’s dual listing on the OTCQB in the US under ticker VHLUF also attracts international investor interest, particularly in digital health and remote patient monitoring sectors.<\/p>
